RECEPTOR INTERACTING PROTEIN 2 (RIP2) IN DEVELOPMENT OF IMMUNE RESPONSE
UCLA Technology Available For Licensing

UCLA investigators have determined that Receptor Interacting Protein 2 (RIP2) has novel functions in regulating Th1 helper T cells and the IL-1/IL-18Toll-like receptor responses of NK cells and presents a target for therapeutic approaches to the treatment of disorders mediated by these cells, including toxic shock and certain autoimmune diseases.

Their results suggest that RIP2 plays a pivotal role in Th1 and NK cell-mediated immune responses and that its regulation should provide a therapeutic approach to the treatment of disorders mediated by these cells, such as toxic shock and of certain autoimmune diseases.

Reference: UCLA Case No. 2001-425

For additional technical details and current licensing
availabilty, please contact the following UCLA office:

UCLA Office of Intellectual Property
11000 Kinross Avenue, Suite #200
Los Angeles, CA 90095-7231
Tel: 310-794-0558 Fax: 310-794-0638
email: ncd@resadmin.ucla.edu
Lead Inventor: Genhong Cheng

UCLA Technologies Available for Licensing
http://www.research.ucla.edu/tech

Copyright © 2001 The Regents of the University of California.

keywords: therapeutics uclancd ucla technologies intellectual property patents technology transfer invention business card